Attovia registers Phase 1 trial of ATTO-1091 for ulcerative colitis
Attovia Therapeutics has filed a new Phase 1 study of ATTO-1091, testing safety, tolerability and pharmacokinetics in healthy volunteers and ulcerative colitis patients.
Attovia Therapeutics had one clinical trial update this week.
- ATTO-1091, a Phase 1 drug candidate for ulcerative colitis, was newly registered with a status of "not yet recruiting" ahead of an estimated start date of December 14, 2026. The trial is a 3-part study, with Parts 1 and 2 assessing single and multiple ascending doses in healthy adult volunteers and Part 3 testing multiple doses in adult participants with ulcerative colitis1. The study plans to enroll 96 participants (estimated)1, with a primary outcome measuring incidence of adverse events over 0-169 days for the single ascending dose portion, 0-204 days for the multiple ascending dose portion in healthy volunteers, and 0-141 days for the multiple ascending dose portion in ulcerative colitis patients1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.